Replies to post #299 on Equity Field Notes from temporal sources

[DanWebzster]

STML has a PDUFA date 2/21/19 in a rare, but unmet oncology need.

FDA approval is high probability.

Traders must balance STML's need for capital with the promise of their pipeline.

STML has three promising cancer drugs.

Cash runway extends into mid/19

PGNX may be a decent analog for STML's equity arc.